Response to growth hormone treatment in very young patients with growth hormone deficiencies and mini-puberty
Erdeve, Senay Savaş
Jones, Filiz Mine Çizmecioğlu
Papatya, Esra Deniz
Özbek, Mehmet Nuri
MetadataShow full item record
CitationÇetinkaya, S., Poyrazoğlu, Ş., Baş, F., Ercan, O., Yıldız, M., Adal, E. ... Darendeliler, F. (2018). Response to growth hormone treatment in very young patients with growth hormone deficiencies and mini-puberty. Journal of Pediatric Endocrinology & Metabolism, 31(2), 175-184. https://dx.doi.org/10.1515/jpem-2017-0123
Background: The aim of the study was to assess the response to growth hormone (GH) treatment in very young patients with GH deficiency (GHD) through a national, multi-center study. Possible factors affecting growth response were assessed (especially mini-puberty). Methods: Medical reports of GHD patients in whom treatment was initiated between 0 and 3 years of age were retrospectively evaluated. Results: The cohort numbered 67. The diagnosis age was 12.4 +/- 8.6 months, peak GH stimulation test response (at diagnosis) as 1.0 +/- 1.4 ng/mL. The first and second years length gain was 15.0 +/- 4.3 and 10.4 +/- 3.4 cm. Weight gain had the largest effect on first year growth response; whereas weight gain and GH dose were both important factors affecting second year growth response. In the multiple pituitary hormone deficiency (MPHD) group (n = 50), first year GH response was significantly greater than in the isolated GH deficiency (IGHD) group (n = 17) (p = 0.030). In addition first year growth response of infants starting GH between 0 and 12 months of age (n = 24) was significantly greater than those who started treatment between 12 and 36 months of age (n = 43) (p <0.001). These differences were not seen in the second year. Delta Length/height standard deviation score (SDS), Delta body weight SDS, length/height SDS, weight SDS in MPHD without hypogonadism for the first year of the GH treatment were found as significantly better than MPHD with hypogonadism. Conclusions: Early onsets of GH treatment, good weight gain in the first year of the treatment and good weight gain-GH dose in the second year of the treatment are the factors that have the greatest effect on length gain in early onset GHD. The presence of the sex steroid hormones during minipubertal period influence growth pattern positively under GH treatment (closer to the normal percentage according to age and gender).
WoS Q KategorisiQ3
SourceJournal of Pediatric Endocrinology & Metabolism
- Makale Koleksiyonu 
- PubMed İndeksli Yayınlar Koleksiyonu 
- Scopus İndeksli Yayınlar Koleksiyonu 
- WoS İndeksli Yayınlar Koleksiyonu 
Showing items related by title, author, creator and subject.
Strategic design and high-growth firms: A case from Turkey Sözüer, Aytuğ; Bozaykut Bük, Tuba (Springer, 2018)This chapter focuses on the elements of entrepreneurship and high firm growth phenomenon through a case analysis. The study first defines the fundamental concepts of entrepreneurship and its use as a strategy to yield above ...
Comparison of different growth curves in the assessment of extrauterine growth restriction in very low birth weight preterm infants Yazıcı, Aybüke; Büyüktiryaki, Mehmet; Sarı, Fatma Nur; Akın, Mustafa Şenol; Ertekin, Ömer; Alyamaç Dizdar, Evrim (Elsevier Masson s.r.l., 2023)Background: Preterm infants are at risk of extrauterine growth restriction (EUGR) and associated complications in the long term. Growth curves are important in assessing postnatal growth in these infants. The aim of this ...
Common polymorphisms of growth hormone: Growth hormone receptor axis in Turkish children with short stature Yılmaz Güleç, Elif; Ercan, Oya; Adal, Servet Erdal; Buyru, Ayşe Nur; Yıldız, Metin; Deviren, Ayhan (AVES, 2022)Objective: A single-nucleotide polymorphism of the growth hormone 1 gene, GH1IVS4+90A>T (rs2665802), associated with short stature and a polymorphism of the growth hormone receptor gene, exon 3 deleted variant, associated ...